IMR 687

Drug Profile

IMR 687

Alternative Names: IMR-687

Latest Information Update: 24 May 2017

Price : $50

At a glance

  • Originator Lundbeck A/S
  • Developer Imara Inc
  • Class Small molecules
  • Mechanism of Action Phosphodiesterase 9A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Sickle cell anaemia

Most Recent Events

  • 24 May 2017 Chemical structure information added
  • 15 May 2017 IMR 687 receives Rare Paediatric Disease designation from the FDA for Sickle cell anaemia
  • 15 May 2017 Imara plans a phase II trial for Sickle cell anemia in paediatrics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top